Carna Biosciences (TSE:4572) FCF Margin % : 0.00% (As of Jun. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Carna Biosciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Carna Biosciences's Free Cash Flow for the three months ended in Jun. 2024 was 円0 Mil. Carna Biosciences's Revenue for the three months ended in Jun. 2024 was 円135 Mil. Therefore, Carna Biosciences's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.

As of today, Carna Biosciences's current FCF Yield % is -23.69%.

The historical rank and industry rank for Carna Biosciences's FCF Margin % or its related term are showing as below:

TSE:4572' s FCF Margin % Range Over the Past 10 Years
Min: -157.2 Med: -80.87 Max: 44.76
Current: -117.21

During the past 13 years, the highest FCF Margin % of Carna Biosciences was 44.76%. The lowest was -157.20%. And the median was -80.87%.

TSE:4572's FCF Margin % is ranked better than
52.95% of 1050 companies
in the Biotechnology industry
Industry Median: -143.325 vs TSE:4572: -117.21

Carna Biosciences FCF Margin % Historical Data

The historical data trend for Carna Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carna Biosciences FCF Margin % Chart

Carna Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

44.76

-117.34

-78.23

-60.17

-103.88

Carna Biosciences Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Carna Biosciences's FCF Margin %

For the Biotechnology subindustry, Carna Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Carna Biosciences's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Carna Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Carna Biosciences's FCF Margin % falls into.

Carna Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Carna Biosciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-1688.994	/	1625.889
	=	-103.88 %

Carna Biosciences's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	0	/	134.772
	=	0.00 %

Carna Biosciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Carna Biosciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Carna Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Carna Biosciences Inc (TSE:4572) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047

Website

http://www.carnabio.com

Carna Biosciences, Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines primarily for the treatment of cancer and inflammatory diseases using own innovative kinase drug discovery platform, QuickScout.

Carna Biosciences Headlines

No Headlines